Pramlintide for Glucose Control
Amylin Pharmaceuticals, Inc., has announced the FDA’s approval of pram-lintide acetate (Symlin®) injection to be used in conjunction with insulin to treat type-1 and type-2 diabetes. This product is to be used at mealtime in diabetic patients who have been unable to achieve desired glucose control despite optimal insulin therapy. The self-administered injection causes less [...]





